Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
Madhusudan KabraLuana MargottoFil ManuguidPublished in: Future oncology (London, England) (2021)
Aim: Assess treatment patterns and healthcare resource utilization (HRU) in patients with treatment-naive (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) in Europe. Patients & methods: Cross-sectional, retrospective, web-based survey of AML-treating healthcare professionals (HCPs) in 12 European countries. Results: 320 HCPs provided information on 1280 TN or R/R patients. Patients ineligible versus eligible for intensive induction therapy required more general practitioner visits (4.1 vs 2.4), more uses of healthcare-related transport (6.9 vs 4.5), but less hospitalization (11.4 vs 27.5 days). Differences were observed in HRU and treatment patterns across countries. Conclusions: This analysis of 'real-world' patients with TN or R/R AML in Europe demonstrates substantial healthcare use, including higher use of resources in patients ineligible for intensive induction therapy.
Keyphrases
- acute myeloid leukemia
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- cross sectional
- chronic kidney disease
- peritoneal dialysis
- stem cells
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- mesenchymal stem cells
- bone marrow
- social media
- diffuse large b cell lymphoma
- hiv infected
- smoking cessation
- replacement therapy
- antiretroviral therapy
- hodgkin lymphoma